search
EN
VI
Home
Introduction
Products
Research and development
News
Shareholders relations
close
search
Home
Research and development
Research and development
12.28.2022
Treatment regimen for stomach Helicobacter pylori by the Ministry of Health
Helicobacter pylori (H.p)
bacteria have long been found to live in the mucus layer adjacent to the gastric mucosal epithelium. 60-90% of peptic ulcers are caused by
H.p
. Since 2005 the World Health Organization has officially classified
H.p
as the cause of stomach cancer.
Helicobacter pylori
also causes a number of other diseases in the stomach such as functional dyspepsia. In addition,
H.p
also causes diseases outside the digestive organs: such as primary thrombocytopenia.
Read More
12.21.2022
Initiating Treatment With Cariprazine
Read More
11.28.2022
Reagila clinical studies & Uniqueness in the treatment of Schizophrenia
Read More
11.21.2022
The Mechanism of Action of Cariprazine in Schizophrenia
Read More
11.18.2022
Four Major Dopaminergic Pathways & Association with Schizophrenia
Read More
11.17.2022
Fluconazole – Active ingredient used in the treatment of Candidiasis
Fluconazole belongs to a class of antifungals called triazoles. It works by slowing the growth of fungi that cause infection. Fluconazole is used to treat fungal infections, including yeast infections of the vagina (usually Candida), mouth, throat, esophagus (tube leading from the mouth to the stomach), abdomen (area between the chest and waist), lungs, blood, and other organs. Fluconazole is also used to treat meningitis caused by fungus. Besides, Fluconazole is also used to prevent yeast infections in patients who are likely to become infected.
Read More
11.15.2022
Reagila named Medicine of the Year
Richter's atypical antipsychotic, Reagila, containing the active ingredient cariprazine, was awarded the prize of Medicine of the Year 2019 by the Hungarian Society for Experimental and Clinical Pharmacology (MFT).
Read More
11.14.2022
Overview of current treatment & management of Schizophrenia
Antipsychotic drugs through inhibition of dopamine D2-receptors are effective and are considered the cornerstone pharmacological therapies in the treatment of schizophrenia.
Read More
11.13.2022
FDA Approves Cariprazine for Depression in Bipolar I Disorder
The U.S. Food and Drug Administration (FDA) approved cariprazine for the treatment of depressive episodes in adults with bipolar I disorder.
Read More
1
2
3
›
»